The wide implementation of CD19-directed therapy in the treatment algorithms for both primary and R/R BCP-ALL [5,6,7,45,46,47] significantly complicated the rather routine procedure of MFC-MRD monitoring. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.